Abstract
Antibodies to the microtubule-associated protein tau have been used for more than a decade, both in studies of the role of tau neuronal function, and in examination of the neurofibrillary pathology of Alzheimer’s disease (AD). The vast majority of the available antibodies have been produced with preparations obtained from the brains of patients with AD, although a few antibodies have been generated with tau purified from bovine brain. This chapter restricts discussion to the production and characterization of monoclonal antibodies, although some investigators continue to use affinity-purified polyclonal antibodies. The opinions expressed in this chapter are based on the author’s experience in the production of several series of monoclonal antibodies to tau and paired helical filaments (PHF-tau) over the last 10 yr. There is no doubt that modifications in the procedures described can be developed for specific purposes, but the discussion is confined to those methods that we have found to be reliable and informative.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brandt, R., Kempf, M., and Lee, G. (1997) Expression and purification of tau for in vitro studies, in Brain Microtubule-Associated Proteins: Practical Approaches (Avila, J., Brandt, R., and Kosik, K. S., eds.), Harwood Academic Publishers, pp. 245–257.
Vallee, R. B. (1982) A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs). J. Cell Biol. 92, 435–442.
Greenberg, S. G. and Davies, P. (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87, 5827–5831.
Vincent, I. J. and Davies, P. (1992) A protein kinase associated with the paired helical filaments in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 89, 2878–2882.
de St. Groth, S. F. and Scheidegger, D. (1980) Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35, 1–21.
Szendrei, G. I., Lee, V. M., and Otvos, L., Jr. (1993) Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J. Neurosci. Res. 34, 243–249.
Kalcheva, N., Albala, J. S., Binder, L. I., and Shafit-Zagardo, B. (1994) Localization of specific epitopes on human microtubule-associated protein 2. J. Neurochem. 63, 2336–2341.
Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996) The structural basis of monoclonal antibody Alz50′s selectivity for Alzheimer’s disease pathology. J. Biol. Chem. 271, 32,789–32,795.
Ksiezak-Reding, H., Chien, C. H., Lee, V. M., and Yen, S.-H. (1990) Mapping of the Alz 50 epitope in microtubule-associated proteins tau. J. Neurosci. Res. 25, 412–419.
Goedert, M., Spillantini, M. G., and Jakes, R. (1991) Localization of theAlz-50 epitope in recombinant human microtubule-associated protein tau. Neurosci. Lett. 126, 149–154.
Jicha, G. A., Bowser, R., Kazam, I. G., and Davies, P. (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conforma-tional epitopes on recombinant tau. J. Neurosci. Res. 48, 128–132.
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., van de Voorde, A., Martin, J. J., and Cras, P. (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828–1834.
Johnson, G. V., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., and Galasko, D. (1997) The tau protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J. Neurochem. 68, 430–433.
Jicha, G. A., Berenfeld, B., and Davies, P. (1998) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer’s disease. J. Neurosci. Res. 55, 713–723.
Schweers, O., Schonbrunn-Hanebeck, E., Marx, A., and Mandelkow, E. (1994) Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta structure. J. Biol. Chem. 269, 24,290–24,297.
Jicha, G. A., O’Donnell, A., Weaver, C., Angeletti, R., and Davies, P. (1998) Hierarchical phosphorylation of recombinant tau by the paired helical filament 373 associated protein kinase is dependent on cAMP-dependent protein kinase. J. Neurochem. 72, 214–224.
Ksiezak-Reding, H., Liu, W. K., and Yen, S.-H. (1992) Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597, 209–219.
Greenberg, S. G., Davies, P., Schein, J. D., and Binder, L. I. (1992) Hydrofluoric acid-treated tau-PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564–569.
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., and Ihara, Y. (1992) Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain. J. Biol. Chem. 267, 17,047–17,054.
Matsuo, E. S., Shin, R. W., Billingsley, M. L., Van deVoorde, A., O’Connor, M., Trojanowski, J. Q., and Lee, V. M. (1994) Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron 13, 989–1002.
Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., and Cras, P. (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: identification of phosphorylation sites in tau protein. Biochem. J. 301, 871–877.
Otvos, L. Jr., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., and Lee, V. M. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669–673.
Jicha, G. A., Lane, E., Vincent, I. J., Otvos, L., Hoffmann, R., and Davies, P. (1997) A conformation and phosphorylation dependent antibody recognizing the paired helical filaments of Alzheimer’s disease. J. Neurochem. 69, 2087–2095.
Hoffmann, R., Lee, V. M., Leight, S., Varga, I., and Otvos, L. Jr. (1997) Unique Alzheimer’s disease paired helical filament specific epitopes involve double-phos-phorylation at specific sites. Biochemistry 36, 8114–8124.
Vincent, I.J., Rosado, M., and Davies, P. (1996)MitoticmechanismsinAlzheimer’s disease? J. Cell. Biol. 132, 413–425.
Bowser, R., Giambroni, M. A., and Davies, P. (1995) FAC1, a novel gene identified with the monoclonal antibody Alz50, is developmentally regulated in human brain. Devel. Neurobiol. 17, 20–37.
Schoonover, S., Jicha, G., Kazam, I., Davies, P., and Bowser, R. (1995) A novel antibody to a primary sequence epitope of tau recognizes neuritic lesions in Alzheimer’s disease. Alzheimer’s Res. 1, 35–40.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Davies, P. (2000). Characterization and Use of Monoclonal Antibodies to Tau and Paired Helical Filament Tau. In: Hooper, N.M. (eds) Alzheimer's Disease. Methods in Molecular Medicine™, vol 32. Humana Press. https://doi.org/10.1385/1-59259-195-7:361
Download citation
DOI: https://doi.org/10.1385/1-59259-195-7:361
Publisher Name: Humana Press
Print ISBN: 978-0-89603-737-3
Online ISBN: 978-1-59259-195-4
eBook Packages: Springer Protocols